The current price of OBIO is $5.62 — it has decreased by 6.33% since the previous close. Data as of Nov 5, 2026.
OBIO is down 7.41% over the past week, down 3.77% over the past month and up 47.51% over the past year. The price is above its 200-day moving average of $4.56.
Analysts' average 12-month price target for OBIO is $10.75, which implies 91.28% upside from the current price. Individual estimates range from $10.00 to $13.00.
Of the 7 analysts covering Orchestra BioMed Holdings, Inc., 1 rates it a strong buy and 6 rate it a buy. The overall consensus is bullish. Analyst ratings are opinions and do not guarantee future performance.
Orchestra BioMed Holdings, Inc. has a market capitalization of $337.79M. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.
In its most recent quarterly report, Orchestra BioMed Holdings, Inc. posted a loss of $0.38 per share against an estimate of -$0.392, beating expectations by 3.06%. Upcoming reports are listed in the earnings calendar.
Orchestra BioMed Holdings, Inc. reported revenue of $88K in its most recent quarter, which has decreased by 89.47% compared with the same quarter a year earlier. Analysts had expected $137.71K.
Orchestra BioMed Holdings, Inc. has not paid any dividends over the past year.
Companies most comparable to Orchestra BioMed Holdings, Inc. include Eupraxia Pharmaceuticals Inc., Avalo Therapeutics, Inc., Enanta Pharmaceuticals, Inc., Prelude Therapeutics Incorporated and Inventiva S.A.
In the latest trading session OBIO moved between $5.60 and $6.00, a range of 7.12% of its current price.
Investing in stocks requires thorough research: study the company's financials, related news and technical analysis before making a decision. Technical analysis of Orchestra BioMed Holdings, Inc. shows a sell rating today and a buy rating on the weekly timeframe. Technical ratings are indicators, not investment advice.
Over the past 52 weeks OBIO has traded between $3.46 and $6.50. The current price is 13.54% below its 52-week high.
Figures as of Nov 5, 2026. This information is provided for general purposes only and is not investment advice.